Company executives discussed the potential of Cobenfy for various treatments, with a focus on Alzheimer's disease. Bristol Myers Squibb plans to release late-stage trial data for Alzheimer's-related psychosis soon, aiming for $10 billion peak sales across different uses by 2030.